ArticleClinical rheumatology2026
Cost-efficiency of imaging strategies for detecting subclinical atherosclerosis in psoriatic arthritis.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cardiovascular Risk in Psoriatic Arthritis in the Treat-to-Target Era: A Focused Expert Narrative Review of Epidemiology, Risk Assessment, Vascular Imaging, and Prevention.Journal of clinical medicine · 2026Review
- Multisite Atherosclerosis and SCORE2-Based Risk Stratification in Psoriatic Arthritis: A Phenotype-Dependent Role of Vascular Territories.Biomedicines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with psoriatic arthritis (PsA) face increased cardiovascular (CV) risk, but conventional calculators such as SCORE tend to underestimate it. Imaging of subclinical atherosclerosis may help refine risk stratification. However, the relative cost-efficiency of available modalities has not been systematically compared.
objectivesTo evaluate the diagnostic yield and cost-efficiency of femoral ultrasound, carotid ultrasound, and abdominal X-ray in detecting subclinical atherosclerosis among PsA patients.
methodsA cross-sectional PsA cohort (N = 146) fulfilling CASPAR criteria was studied. Ultrasound of femoral and carotid arteries and abdominal X-ray imaging were performed. Unit costs were estimated from typical European healthcare tariffs: ultrasound €50-150; abdominal X-ray €20-50. Cost per detected case was calculated as = unit cost × NNS (number needed to screen to detect a case). A threshold condition was derived to establish when X-ray becomes more cost-efficient than vascular ultrasound: Cost (Rx) < 0.4985 × Cost (US).
resultsFemoral ultrasound yielded the best diagnostic performance (NNS 1.62; cost per case €81-243). Carotid ultrasound was less efficient (NNS 2.98; €149-447). Abdominal X-ray, despite lower plaque prevalence (30.8%), was the most cost-efficient option (€65-162.5 per case), as long as its price remained < 50% of the ultrasound cost.
conclusionsFemoral artery ultrasound provides the highest diagnostic yield for subclinical atherosclerosis in PsA, while abdominal X-ray may represent a pragmatic, low-cost alternative for detecting calcified lesions. Carotid ultrasound appears less efficient. These findings highlight the need to balance diagnostic yield, cost, and clinical objectives in CV risk management for PsA. Key points • Femoral ultrasound provided the highest diagnostic yield for detecting subclinical atherosclerosis in PsA patients. • Carotid ultrasound was less efficient, identifying plaques with higher cost and lower sensitivity than femoral scans. • Abdominal X-ray was the most cost-efficient option when priced below half the ultrasound cost. • Imaging strategy in PsA should balance diagnostic yield, economic factors, and healthcare resource availability.
Indexed as
Identifiers
41203928What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.